Dongkoo Bio&Pharma
4
20M
4
1
- Areas of investment
Summary
Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Neuraly. Among the most successful fund investment fields, there are Health Care, Biotechnology.
The top activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The usual cause for the fund is to invest in rounds with 9 partakers. The meaningful sponsors for the fund in investment in the same round are Smilegate Investment, Octave Life Sciences, Maryland Venture Fund.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 1
- Investments by industry
- Pharmaceutical (2)
- Biotechnology (2)
- Food Delivery (1)
- Retail (1)
- Food and Beverage (1) Show 3 more
- Investments by region
-
- United States (2)
- South Korea (2)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 4
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| My Chef | 14 May 2021 | Retail, Food and Beverage, Food Delivery | Early Stage Venture | Seoul, Seoul-t'ukpyolsi, South Korea |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.